Redeye provides a research update on Scandinavian ChemoTech following the Q4 2023 report and the retracted sales target in India. The company delivered a quarterly report that fell short of Redeye's estimates. Sales came in lower than anticipated, and OPEX was slightly higher, most likely due to some one-off items. On a positive note, a fifth commercial installation has been carried out on the US market and a TAM-expanding amendment to the study protocol at AIIMS Jodhpur has been announced.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Scandinavian ChemoTech - Weathering the storm

© Modular Finance, source Nordic Press Releases